Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain block could cut opioid use after heart surgery

NCT ID NCT04648774

Symptom relief Sponsor: Nova Scotia Health Authority Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a nerve block called the serratus anterior plane (SAP) block can reduce pain and opioid use after heart surgery. Fifty adults having valve or bypass surgery through a chest incision will receive either the numbing drug ropivacaine or a placebo through small catheters for 72 hours. The study focuses on whether a larger trial is feasible and measures pain, recovery quality, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ropivacaine 0.2%
What this could lead to
If it works, this nerve block could reduce the need for strong painkillers after heart surgery, leading to faster recovery and fewer side effects.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to everyone. The block itself carries small risks like pneumothorax or allergic reaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jul 2021

Finished

Aug 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (aged \>18 years) patients at time of screening * Undergoing valvular replacement/repair and/or coronary artery bypass grafting (CABG) * via median sternotomy Exclusion Criteria: * Surgery on an emergency basis (level 1 or 2, \<2 hours) * An ejection fraction \<30% * Patient on extracorporeal membrane oxygenator (ECMO), * Presence of an intra-aortic balloon pump (IABP) * Preoperative vasopressors or inotropes * Severe pre-existing liver disease (Child B or C) * Severe kidney disease (Glomerular filtration rate (GFR) \<30 (mL/min/1·73m²)) * An allergy to ropivacaine * Planned circulatory arrest * BMI \>35 * Weight \<50 kg * Opioid tolerant (oral morphine equivalent \>60mg per day for \>1 week prior to admission) * Unable to provide valid consent to study prior to surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opioid abuse Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use Postoperative pain Quality of life

Contacts and locations

Locations

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3S 0H6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.